Literature DB >> 9559820

Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones.

X Zhao1, J Y Wang, C Xu, Y Dong, J Zhou, J Domagala, K Drlica.   

Abstract

C-8-methoxy fluoroquinolones were more lethal than C-8-bromine, C-8-ethoxy, and C-8-H derivatives for Staphylococcus aureus, especially when topoisomerase IV was resistant. The methoxy group also increased lethality against wild-type cells when protein synthesis was inhibited. These properties encourage refinement of C-8-methoxy fluoroquinolones to kill staphylococci.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9559820      PMCID： PMC105579          DOI： 10.1128/AAC.42.4.956

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance.

Authors:  X Zhao; C Xu; J Domagala; K Drlica
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

2.  Protein- and RNA-synthesis independent bactericidal activity of ciprofloxacin that involves the A subunit of DNA gyrase.

Authors:  C S Lewin; B M Howard; J T Smith
Journal:  J Med Microbiol       Date:  1991-01       Impact factor: 2.472

3.  The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.

Authors:  J P Sanchez; R D Gogliotti; J M Domagala; S J Gracheck; M D Huband; J A Sesnie; M A Cohen; M A Shapiro
Journal:  J Med Chem       Date:  1995-10-27       Impact factor: 7.446

4.  Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.

Authors:  L Ferrero; B Cameron; B Manse; D Lagneaux; J Crouzet; A Famechon; F Blanche
Journal:  Mol Microbiol       Date:  1994-08       Impact factor: 3.501

5.  Mechanism of action of nalidixic acid on Escherichia coli. 3. Conditions required for lethality.

Authors:  W H Deitz; T M Cook; W A Goss
Journal:  J Bacteriol       Date:  1966-02       Impact factor: 3.490

6.  In vitro antibacterial activity of Q-35, a new fluoroquinolone.

Authors:  T Ito; M Otsuki; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

7.  In vitro and in vivo activities of clinafloxacin, CI-990 (PD 131112), and PD 138312 versus enterococci.

Authors:  M A Cohen; S L Yoder; M D Huband; G E Roland; C L Courtney
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

8.  Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.

Authors:  A Bauernfeind
Journal:  J Antimicrob Chemother       Date:  1993-04       Impact factor: 5.790

9.  Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa.

Authors:  A Kitamura; K Hoshino; Y Kimura; I Hayakawa; K Sato
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

10.  Improved bactericidal activity of Q-35 against quinolone-resistant staphylococci.

Authors:  T Ito; M Matsumoto; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191
View more
  30 in total

1.  Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus.

Authors:  Y Dong; X Zhao; J Domagala; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

2.  Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.

Authors:  Xinying Li; Xilin Zhao; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

3.  Propensity of fluoroquinolones with different moieties at position 8 to cause resistance development in clinical isolates of Streptococcus pneumoniae.

Authors:  F J Schmitz; M Boos; S Mayer; D Hafner; H Jagusch; J Verhoef; A C Fluit
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

4.  Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae.

Authors:  H Fukuda; R Kishii; M Takei; M Hosaka
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

5.  Contribution of the C-8-methoxy group of gatifloxacin to inhibition of type II topoisomerases of Staphylococcus aureus.

Authors:  Masaya Takei; Hideyuki Fukuda; Ryuta Kishii; Youko Kadowaki; Yukiko Atobe; Masaki Hosaka
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

Review 6.  Quinolone-mediated bacterial death.

Authors:  Karl Drlica; Muhammad Malik; Robert J Kerns; Xilin Zhao
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

7.  Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol.

Authors:  Muhammad Malik; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

8.  Comparative mutant prevention concentrations of pradofloxacin and other veterinary fluoroquinolones indicate differing potentials in preventing selection of resistance.

Authors:  H-G Wetzstein
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

9.  In vitro activity of fluoroquinolones against clinical isolates of Nocardia identified by partial 16S rRNA sequencing.

Authors:  G Hansen; S Swanzy; R Gupta; B Cookson; A P Limaye
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11-09       Impact factor: 3.267

10.  Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance.

Authors:  Y Dong; C Xu; X Zhao; J Domagala; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.